Mauritius Telecom and Aprecomm Come Together to Bring Innovation to Customer Experience With Network Intelligence
Mauritius Telecom, the largest ISP in Mauritius with cellular and high-speed broadband service distribution, today announced its intent to bring Artificial Intelligence based innovative technology to enhance visibility and optimize its residential Wi-Fi connections through a partnership with Aprecomm. This A.I. technology will help Mauritius Telecom to bring proactive Network Intelligence transformation to improve customer experience and to drastically reduce the time for resolution of customer-end issues across their broadband network covering more than 300,000 households.
Speaking on the development, Mr. Kapil Reesaul, CEO, Mauritius Telecom, said, “Mauritius Telecom is the forefront runner in continuous investments in technology to keep innovating and providing the best service to its consumers. The partnership with Aprecomm will help us in our efforts to ensure the best experience across our broadband consumers with faster and proactive resolution of potential issues.”
Pramod Gummaraj, CEO, Aprecomm, said, “We're excited to team up with Mauritius Telecom and implement cutting-edge technology into their network in order to help them cut down on support ticket response times by as much as half and provide a dramatically better experience for their customers. Network Innovation focused on customer experience could be deployed across in the coming months.”
The measurable improvements offered by the integration between Mauritius Telecom and Aprecomm also lead to lower maintenance cost and improved customer satisfaction for one of the country’s fastest growing ISPs.
“With Aprecomm’s vendor agnostic technology, Mauritius Telecom will be able to manage and monitor Network Elements through a unified interface, ensuring assured internet experience to their customers,” said Guharajan Sivakumar, CTO, Aprecomm.
“Network Automation will allow us to bring the best possible experience to our end customers. Measurable customer experience and proactive actions to improve it will be part of this partnership as Aprecomm technology is aligned towards Network Automation,” said Mr. Yagianath Rosunee, CTO of Mauritius Telecom.
About Mauritius Telecom
Mauritius Telecom is the leading provider of an extensive range of ICT services and solutions for both residential customers and businesses in Mauritius, including fixed, mobile, broadband, TV, mobile money and ICT services. Mauritius Telecom has played a pivotal role in the socio-economic development of Mauritius, paving the way for the growth of the ICT industry, which has become a major pillar of the Mauritian economy. Mauritius Telecom has taken bold initiatives to transform the lives of Mauritians, deploying fibre island-wide to provide ultra-high-speed broadband to all, disrupting the payment landscape with a mobile wallet thus revolutionizing payments in Mauritius, launching in 2021 the first 5G Experience Zones and the first 1Gbps fibre internet to home offer in Mauritius. In 2022 Mauritius Telecom’s mobile service, my.t mobile reached the milestone of one million customers.
- Headquarters: Port Louis, Mauritius
- Website: https://www.telecom.mu, https://www.myt.mu/
- LinkedIn: https://www.linkedin.com/company/mauritius-telecom/
- Facebook: https://www.facebook.com/mauritiustelecom
About Aprecomm
Aprecomm is an industry game-changer with a Network Intelligence Software Stack to understand Customer Experience. Aprecomm offers cloud-based automated solutions to enhance Wired and Wi-Fi network performance. Aprecomm’s patented technology helps in automatically and proactively troubleshooting Wi-Fi issues. This way ISPs and Enterprises will be able to fix them immediately and dramatically minimize down-time. Aprecomm’s solutions help enterprises, ISPs, TSPs improve their business standards through higher reliability, reduced expenses, and speedy ROI.
- Headquarters: Bangalore, India
- Website: https://aprecomm.ai
- LinkedIn: https://in.linkedin.com/company/aprecomm
- Facebook: https://www.facebook.com/aprecomm/
- Twitter: https://twitter.com/aprecomm_ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005801/en/
Contact information
For further details please contact:
Aprecomm
Shankar Peerthy
Email: Peerthy@aprecomm.ai
Contact: +41-78 685 82 58
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release
TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom